Lixte Biotechnology has signed an exclusive patent license agreement with the National Institute of Neurological Disorders and Stroke and NCI.
Government work isn’t what it used to be.
Lixte Biotechnology enters exclusive immuno-oncology patent license agreement with NINDS, NCI
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
I was really excited to get to talk about the role that mentorship plays in women’s leadership development. It’s a topic that I’ve thought a lot about, and also that I’ve benefitted from, and that I think is not always applied with enough intention. There is an art to mentorship, and I want to share some of how that has helped me navigate career transitions and pivot to leadership roles.
As we are all aware, the new presidential administration is moving rapidly to change how science, including health sciences, will be conducted and funded by the federal government, including research supported by the National Institutes of Health.
Former NCI Director W. Kimryn Rathmell was awarded the American Cancer Society 2025 Medal of Honor.
Researchers from the University of Chicago Medicine Comprehensive Cancer Center demonstrated the potential of a novel treatment approach including immunotherapy to treat advanced human papillomavirus-negative head-and-neck squamous cell carcinoma. More than half of study participants had 50% or more of their tumors shrink after receiving the immunotherapy drug nivolumab with chemotherapy, followed by response-adaptive chemo-radiation therapy.
UT Southwestern Medical Center researchers developed a “self-driving” microscope that solves two challenges that have long plagued microscopy: 1) imaging living cells or organisms at dramatically different scales, and 2) following a specific structure or area of interest over long periods of time.
